Skip to contentI
IDEAYA Biosciences, Inc.
I
IDYAIDEAYA Biosciences, Inc. Q2 2022 · 10-Q
Revenue$5.85M$5.85M−33.2% vs Q2 2021 Net Income-$22.06M-$22.06MN/M vs Q2 2021 EPS Diluted-$0.57-$0.57N/M vs Q2 2021 Operating Income-$22,499,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
IDEAYA Biosciences, Inc. · CIK 1676725 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$21,933,000N/M Margins · derivedOperating margin-384.5%−258.3 pt vs Q2 2021
Net margin-377.0%−251.9 pt vs Q2 2021
ended Jun 30, 2022 · filed Aug 15, 2022 · 46 d after period end